A comparison of hypersensitivity reactions between intravenous and intramuscular applications of native E. coli asparaginase in children with acute lymphoblastic leukemia.
| Autor: | Odaman Al I; Department of Pediatric Hematology and Oncology, İstanbul Medipol University Medical Faculty, İstanbul, Turkey., Özdemir N; Department of Pediatric Hematology and Oncology, İstinye University Medical Faculty, İstanbul, Turkey., Zengin Ersoy G; Department of Pediatric Hematology and Oncology, Altınbaş University Medical Faculty, İstanbul, Turkey., Bayram C; Department of Pediatric Hematology and Oncology, Çam and Sakura City Hospital, İstanbul, Turkey., Vupa Çilengiroğlu Ö; Faculty of Sciences, Department of Statistics, Dokuz Eylul University, Izmir, Turkey., Arslantaş E; Department of Pediatric Hematology and Oncology, Çam and Sakura City Hospital, İstanbul, Turkey., Paslı Uysalol E; Department of Pediatric Hematology and Oncology, Çam and Sakura City Hospital, İstanbul, Turkey., Ayçiçek A; Department of Pediatric Hematology and Oncology, Çam and Sakura City Hospital, İstanbul, Turkey. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2023 Sep; Vol. 29 (6), pp. 1454-1460. Date of Electronic Publication: 2023 Mar 20. |
| DOI: | 10.1177/10781552231164503 |
| Abstrakt: | Introduction: Asparaginase is an indispensable drug in treating childhood acute lymphoblastic leukemia (ALL). Hypersensitivity reactions (HSR) are the most common side effects and interfere with the antineoplastic activity of the drug. This study aims to compare the intramuscular (IM) and intravenous (IV) administration routes of Native Escherichia coli Lasparaginase (L-ASNase) in terms of hypersensitive reactions. Methods: L-ASNase was randomly administered IV or IM to newly diagnosed ALL patients and HSR was monitored in all patients for 1 h following the end of the IV infusion and for 2 h following the end of the IM administration of L-ASNase. Based on a retrospective review of clinical charts, reactions were identified. In order to determine the severity of each allergic reaction, we used the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 for allergic reactions. Results: A total of 1032 doses of L-ASNase were administered to 85 patients (42 males and 43 females) during the study period. Among 85 patients, 30 reactions were recorded, which means that 35% of the patients reacted. According to the CTCAE, twenty-nine out of 30 reactions (97%) were grade 2, while one (3%) was grade 4. In terms of individual doses, there was a non-significant trend toward increased incidence of reactions with IV administration (3.8% versus 0.9%, p = 0.064). The rate of reactions was higher in patients who received all IV doses ( n : 60) as compared to those who received all IM doses ( n : 25) (31.7% vs. 3.5%; chi-square= 8.415, p value=0.04). Based on the risk groups and HSR incidence, it was found that high risk group (HRG) patients were significantly more likely to develop HSR compared to the standart risk group (SRG) and intermediate risk group (MRG) patients (chi-square p = 0.003, CI: 95%; odds ratio: 3.12 and 5.91, respectively). Conclusions: In conclusion, IM administration of L-ASNase causes significantly less HSR to L-ASNase than the IV route. Patients with HRGALL have a higher risk of HSR. Since L-ASNase is still used in many developing countries and there are problems in the supply of Erwinia chrysanthemi ASNase (Erwinia), LASNase can be administered IM to reduce the frequency of HSR. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|